Rehospitalization Reductions After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer

Medical Device Investing

Daxor (NYSE:DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of new data in the Journal of the American College of Cardiology – Heart Failure showing statistically significantly reduced 30-day readmission and 30-day and 1-year mortality rates in patients who received individualized treatment for acute heart failure guided by …

Daxor (NYSE:DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of new data in the Journal of the American College of Cardiology – Heart Failure showing statistically significantly reduced 30-day readmission and 30-day and 1-year mortality rates in patients who received individualized treatment for acute heart failure guided by blood volume measurement with the BVA-100 blood volume analyzer, compared to propensity-matched controls.

As quoted in the press release:

“This is a landmark study for Daxor as it provides peer review validation in a leading cardiology journal of the value of our technology and its potential to improve heart failure outcomes. Heart failure represents one of the largest areas of healthcare spending and one of the most significant treatment challenges for approximately 6 million US patients, which is expected to double as the population ages,” commented Michael Feldschuh, CEO of Daxor. “The BVA-100 provides a simple, rapid, inexpensive, non-invasive, and most importantly, objective measurement of volume status and composition. This precision enables individualization of treatment and significantly better outcomes for patients.”

Treatment guided by the BVA-100 blood volume analyzer resulted in a statistically significant decrease in rehospitalization (12.2 percent vs. 27.7 percent, p<0.001), 30-day mortality (2.0 percent vs. 11.1 percent, p<0.001) and 365-day mortality (4.9 percent vs. 35.5. percent, p<0.001), compared to a propensity score control. Further, an analysis of 30-day readmission by diagnosis showed fewer heart failure readmissions (6.1 percent vs. 20.2 percent, p<0.001) and fewer cardiac non-heart failure admissions (1.6 percent vs. 3.9 percent, p<0.001).

Click here to read the full press release.

The Conversation (0)
×